Salidroside ameliorates glucocorticoid-induced osteoporosis by regulating the PI3K/Akt/mTOR pathway: a network pharmacology and in vivo
- 1Department of Orthopedic Surgery, Tangdu Hospital, The Fourth Military Medical University
Abstract
Osteoporosis (OP) is a bone disorder, common cause of bone fracture and disability. Management of it needs development of an alternative medicine and present report evaluates the protective effect of salidroside against glucocorticoid induced osteoporosis in rat model. Network pharmacology and docking study was performed to determine the molecular targets of salidroside against osteoporosis and its interaction with these targets. Twenty-four healthy male rats were separated into four different groups (n = 6) such as control group; OP (Osteoporosis) group and salidroside 50 and 100 mg/kg groups. Osteoporosis was induced by the administration of dexamethasone (5 mg/kg, i.m.) twice in a week for the duration of 6 week and rats were treated with salidroside 50 and 100 mg/kg p.o. for the duration of 8 weeks. Bone mineral density (BMD) and parameters of osteoclast and osteoblast cell function were determined in the salidroside treated OP rats. Oxidative stress and inflammatory cytokines were estimated in OP rats. Data of the network pharmacology and docking study shows the effective binding of salidroside with Phosphoinositide 3-kinase (PI3K; -7.0 Kcal/mol) and Protein kinase B (Akt; -6.1 Kcal/mol) proteins to modulates the cellular function. Moreover, in vivo investigation shows significant increase (p < 0.001) in the BMD of salidroside treated group than OP group of rats. Treatment with salidroside ameliorates the altered level of collagen type I fragments (CTX), tartrate-resistant acid phosphatase (TRAP), osteocalcin (OC) and activity of alkaline phosphatase (ALP) in OP rats. There was significant (p < 0.001) reduction in oxidative stress and cytokines in the salidroside treated group than OP group of rats. mRNA expression of PI3K, Akt and mechanistic target of rapamycin (mTOR) and expression of PI3K, Akt and mTOR proteins were enhanced in the salidroside treated group than OP group of rats. In conclusion, data of the study reveals that treatment with salidroside ameliorates altered osteocyte function in glucocorticoid induced osteoporosis rats by regulating PI3K/Akt/mTOR pathway.
Related
- Dysregulation of the MACF1‐Rab14/KIF16B‐FGFR Vesicular Trafficking Axis Skews MSC Lineage Commitment in Glucocorticoid‐Induced Osteoporosis
- Therapeutic potential of hydroxybenzoic acid and lentinan in mitigating glucocorticoid-induced osteoporosis: an experimental study
- Sphingosine-1-phosphate ameliorates necrotizing enterocolitis by regulating mitochondrial redox homeostasis and gut microbiota.
- Salidroside Regulates Energy Metabolism Reprogramming to Suppress Tumor Proliferation: Mechanisms and Therapeutic Implications
- Salidroside Represses the Viability of Mouse Sertoli Cell Line (TM4 Cells) via Repression of Ldha-Dependent Glycolysis
BibTeX
@article{ren2026salidroside,
title = {{Salidroside ameliorates glucocorticoid-induced osteoporosis by regulating the PI3K/Akt/mTOR pathway: a network pharmacology and in vivo}},
author = {Kun Ren and Ying Huai and Xin Dong and Zhiwen Luo and Xiajun Liang and Peng Wu},
journal = {Scientific Reports},
year = {2026},
month = sep,
doi = {10.1038/s41598-026-73485-9},
url = {https://doi.org/10.1038/s41598-026-73485-9},
note = {CC BY},
}
RIS
TY - JOUR
TI - Salidroside ameliorates glucocorticoid-induced osteoporosis by regulating the PI3K/Akt/mTOR pathway: a network pharmacology and in vivo
AU - Kun Ren
AU - Ying Huai
AU - Xin Dong
AU - Zhiwen Luo
AU - Xiajun Liang
AU - Peng Wu
PY - 2026
DA - 2026/09/01
JO - Scientific Reports
DO - 10.1038/s41598-026-73485-9
UR - https://doi.org/10.1038/s41598-026-73485-9
AB - Osteoporosis (OP) is a bone disorder, common cause of bone fracture and disability. Management of it needs development of an alternative medicine and present report evaluates the protective effect of salidroside against glucocorticoid induced osteoporosis in rat model. Network pharmacology and docking study was performed to determine the molecular targets of salidroside against osteoporosis and its interaction with these targets. Twenty-four healthy male rats were separated into four different groups (n = 6) such as control group; OP (Osteoporosis) group and salidroside 50 and 100 mg/kg groups. Osteoporosis was induced by the administration of dexamethasone (5 mg/kg, i.m.) twice in a week for the duration of 6 week and rats were treated with salidroside 50 and 100 mg/kg p.o. for the duration of 8 weeks. Bone mineral density (BMD) and parameters of osteoclast and osteoblast cell function were determined in the salidroside treated OP rats. Oxidative stress and inflammatory cytokines were estimated in OP rats. Data of the network pharmacology and docking study shows the effective binding of salidroside with Phosphoinositide 3-kinase (PI3K; -7.0 Kcal/mol) and Protein kinase B (Akt; -6.1 Kcal/mol) proteins to modulates the cellular function. Moreover, in vivo investigation shows significant increase (p < 0.001) in the BMD of salidroside treated group than OP group of rats. Treatment with salidroside ameliorates the altered level of collagen type I fragments (CTX), tartrate-resistant acid phosphatase (TRAP), osteocalcin (OC) and activity of alkaline phosphatase (ALP) in OP rats. There was significant (p < 0.001) reduction in oxidative stress and cytokines in the salidroside treated group than OP group of rats. mRNA expression of PI3K, Akt and mechanistic target of rapamycin (mTOR) and expression of PI3K, Akt and mTOR proteins were enhanced in the salidroside treated group than OP group of rats. In conclusion, data of the study reveals that treatment with salidroside ameliorates altered osteocyte function in glucocorticoid induced osteoporosis rats by regulating PI3K/Akt/mTOR pathway.
SN - 2045-2322
ER -